Company news
Dimerix Limited news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
1st ACTION3 site in Japan activated and milestone triggered
May 29, 2025
Successful planned IDMC review of ACTION3 trial
May 21, 2025
Dimerix receives initial upfront payment from Amicus
May 5, 2025
Investor Webinar and Presentation
April 30, 2025
Dimerix Licenses DMX-200 in the US
April 30, 2025
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
April 30, 2025
Trading Halt
April 28, 2025
FDA confirms Proteinuria as Primary Endpoint for US approval
April 27, 2025
S&P DJI Announces March 2025 Quarterly Rebalance
March 7, 2025
Dimerix receives initial upfront payment from FUSO
March 3, 2025
Half-Year Financial Report & Appendix 4D - 31 December 2024
February 24, 2025
First Paediatric Patient Recruited for ACTION3
January 15, 2025
Dimerix enters Development and License Agreement for Japan
January 6, 2025
DMX-200 ACTION3 Phase 3 Trial Part 2 Recruitment Complete
December 29, 2024
Dimerix Receives $7.9M R&D Tax Incentive Rebate
November 14, 2024
NEPTUNE Study Network to Enhance Phase 3 Recruitment in US
October 31, 2024
Project PARASOL Update & Medical Advisory Board Appointment
October 27, 2024
ACTION3 Trial Recruitment and Multiregion Trial Site Update
September 15, 2024
First Paediatric Site Activated and Trial Update
September 11, 2024
First patient enters into Open Label Extension study
September 10, 2024
Preliminary Final Report
August 28, 2024
Adolescent Recruitment into ACTION3 Clinical Trial
July 3, 2024
Dimerix and Taiba enter into License Agreement for DMX-200
May 26, 2024
Dimerix Receives PIP Approval from the UK MHRA
April 30, 2024
Dimerix Completes $20M Placement
March 11, 2024
Dimerix Successfully Passes Efficacy Interim Analysis
March 10, 2024
PH3 Data Collection Complete for First Interim Analysis
February 26, 2024
Half-Year Financial Report & Appendix 4D - 31 December 2023
February 25, 2024
ACTION3 IND Approved in China
November 27, 2023
Dimerix Receives Initial Upfront Payment from Advanz Pharma
November 5, 2023
Dimerix Announces License Agreement for EU, Canada, ANZ
October 4, 2023
FDA Approves Qytovra Brand Name
September 24, 2023
Regulatory Approval received in Malaysia for ACTION3 Study
September 21, 2023
Dimerix Receives $8.9M R&D Tax Incentive Rebate
September 12, 2023
Successful Completion of 2nd DSMB Review of FSGS Trial
August 7, 2023
DMX-200 FSGS PH3 Kidney Trial Part 1 Outcome set for Q1 CY24
July 23, 2023
Approval received for Paediatric Investigation Plan from EMA
July 4, 2023
Dimerix confirms Phase 3 study design appropriate for China
July 2, 2023
Prospectus
June 26, 2023
Dimerix Announces Update on Successful Capital Raise
June 5, 2023
Rights Issue Prospectus
May 4, 2023
Reinstatement to Official Quotation
May 3, 2023
Entitlement offer and Convertible Note to raise $12 million
May 3, 2023
Voluntary Suspension
May 2, 2023
Half-Year Financial Report & Appendix 4D - 31 December 2022
February 26, 2023
DXB to Receive $2.8m in Prepayment of R&D Tax Incentive
February 16, 2023
Successful Completion of DSMB Review of Phase 3 FSGS Trial
February 8, 2023
FDA Confirms Inclusion of Paediatrics in ACTION3 Study
January 11, 2023
DMX-200 FSGS Phase 3 Trial Part 1 Recruitment Achieved
December 14, 2022
CLARITY 2.0 COVID-19 Study Outcome
December 12, 2022
Decks
The 5 newest of 86 decks. Every deck is listed under its year.
- Technical Presentation (October 2026)
Technical · 17 slides · Oct 23, 2026
- Canaccord Genuity Drug and Device Conference 2026
Conference · 35 slides · Oct 12, 2026
- ASX SMIDcaps Conference 2026
Conference · 16 slides · Sep 23, 2026
- E&P Healthcare Conference 2026
Conference · 22 slides · Sep 16, 2026
- Investor Presentation (September 2026)
Investor deck · 35 slides · Sep 7, 2026